Monte Rosa Therapeutics, Inc. GLUE
11.77
0.05
0.43%
as of 25 Sep
- Market cap
- $999.9M
- P/E
- 0.0×
Follow GLUE
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
|
+8 more TTM periods Free account |
9.28% | (16.94%) | (32.62%) | (42.66%) | |
| 5.41% | (8.71%) | (23.02%) | (30.67%) | ||
ROIC |
0.00% | 0.00% | 0.00% | 0.00% | |
Return on Tangible Assets |
5.69% | (10.88%) | (20.48%) | (26.78%) | |
Average Days of Receivables |
9.98 | 34.24 | 39.17 | 62.51 | |
Free Cash Flow per Share |
1.76 | (0.33) | (0.20) | (0.32) | |
Free Cash Flow |
145.02 | (27.50) | (19.66) | (32.08) | |
Capital Expenditures |
(4.12) | (4.70) | (4.98) | (8.01) | |
Piotroski F-Score |
7.00 | 4.00 | 2.00 | 2.00 | |
| Other line items | |||||
Cash ROIC |
23.41% | (3.74%) | (1.24%) | (2.17%) | |
Accounts Receivable Turnover |
65.30 | 21.01 | 14.28 | 7.88 | |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | |
Tax Rate |
(0.05) | (0.03) | (0.01) | (0.02) | |
Research and Development Expense of Revenue |
76.23% | 114.42% | 357.09% | 594.18% | |
Selling, General and Administrative Expense of Revenue |
19.08% | 29.42% | 88.12% | 138.86% | |
Share Based Compensation of Revenue |
10.48% | 15.25% | 45.44% | 71.68% | |
Interest Coverage |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF/Net income |
7.12 | 0.59 | 0.11 | 0.15 | |
Depreciation/Fixed assets |
0.30 | 0.32 | 0.29 | 0.27 | |
Capex/Depreciation |
(0.49) | (0.56) | (0.60) | (0.99) | |
Revenue per Share |
2.20 | 1.49 | 0.43 | 0.28 | |
Operating CF per Share |
1.81 | (0.27) | (0.15) | (0.24) | |
Capex per Share |
(0.05) | (0.06) | (0.05) | (0.08) | |
Capex to Sales |
0.02 | 0.04 | 0.12 | 0.28 | |
Net Profit Margin |
11.54% | (31.23%) | (302.69%) | (560.85%) |
Columns are period end dates